Sentigen Holding

Sentigen Holding was a biotechnology company specializing in the development of cell-based assay technologies for drug discovery, with a specific focus on G protein-coupled receptors (GPCRs). The company's proprietary Gene-Activated Receptor Assay (GARA) platform enabled the functional analysis of "orphan" receptors and olfactory receptors, providing a unique tool for identifying novel drug candidates. Sentigen's technology was utilized by major pharmaceutical partners to screen large chemical libraries against previously inaccessible targets. The company was headquartered in New York and operated through its subsidiary, Sentigen Biosciences. In late 2006, Sentigen was acquired by Invitrogen Corporation, integrating its receptor screening capabilities into Invitrogen's broader drug discovery services.